Form 4: Corcept Therapeutics Executive William Guyer Reports Stock Option Exercises and Sales

Sentiment:

SEC Form 4 Filing


William Guyer, Chief Development Officer of Corcept Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

  • On November 1, 2024, William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options to acquire 6,606 shares of common stock at a price of $21.65 per share.
  • Simultaneously, Guyer sold 6,606 shares at $48.97 per share.
  • On November 4, 2024, Guyer exercised options for another 3,394 shares at $21.65 and sold 3,394 shares at $48.97.
  • These transactions were executed under a pre-existing 10b5-1 trading plan.
  • Following these transactions, Guyer directly owns 5,796 shares of common stock and 450,000 stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

  • The transactions may provide information to shareholders regarding management's actions with company stock.

Key Dates

DateDescription
August 16, 2021Vesting Commencement Date for stock options
December 1, 2023Grant date of restricted stock units
September 1, 2031Expiration date of stock options
11/01/2024Date of stock option exercise and sale
11/04/2024Date of stock option exercise and sale
11/05/2024Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.